Ridaforolimus — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	1	33	—	—	2003-04
Leukemia	Phase2	Phase 2	0	1	—	—	2004-06
Malignant Breast Neoplasm	Phase2	Phase 2	0	3	—	—	2008-07
Malignant Prostate Neoplasm	Phase2	Phase 2	0	2	—	—

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS Mutation1
Ridaforolimus + Temsirolimus

Clinical trials

Trials with this intervention (33)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–33 of 33 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00694083	Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)	completed	Phase 1	13	Merck Sharp & Dohme LLCINDUSTRY	0	May 21, 2024	clinicaltrials
NCT00770185	Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer	completed	Phase 2